Vedolizumab versus Adalimumab for moderate-to-severe ulcerative colitis

VARSITY Study Group, Juris Pokrotnieks, Ivars Tolmanis

Research output: Contribution to journalArticlepeer-review

251 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Vedolizumab versus Adalimumab for moderate-to-severe ulcerative colitis'. Together they form a unique fingerprint.

Medicine & Life Sciences